Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like it was because of this:
Benchmark Maintains Speculative Buy on Cardio Diagnostics Hldgs, Lowers Price Target to $1.35
7:47 am ET April 19, 2024 (Benzinga) Print
Benchmark analyst Bruce Jackson maintains Cardio Diagnostics Hldgs (NASDAQ:CDIO) with a Speculative Buy and lowers the price target from $4 to $1.35.
Hey RCparker! Thanks for checking in and sorry to hear about the cancer I will send you an e-mail this coming weekend.
Mike
Yes, you don't always have to catch the bottom. I bought BETS this morning at $0.01565. Ride the wave for a while
Yes, PROK looking good!
Looking good!
Probably just because the share price had run up so much before the approval, so it was kind of baked-in already and some took profits. Also, maybe because of high price tag of the treatment. Still a bright future and should trend upwards.
PROK and CYTO: Still have my PROK and bought CYTO at $0.40 this morning. Let's go!
Yes, thanks. Good luck to us
Still have my shares I bought at $0.185 last week. Nice action today!
Thanks for the info
Yes, interesting about TCON. It seems undervalued, and it's above its 20-day and 50-day moving averages
Nice add! Yes, I'm holding PROK.
Don't worry, check TCON next week, but I know how you feel, LOL.
Yes, it has a bright future, and it will help so many patients along the way!
Yes, exciting times!
Nice, Dad! Yeah, December 8th is when we expect FDA approval...
-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)-
ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of SCD in people ages 12 and older with recurrent vaso-occlusive crises (VOCs). Exa-cel is the first potential therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals.
If approved, exa-cel could be the first genetic therapy available to approximately twenty thousand people with severe SCD in the U.S. The FDA granted priority review for exa-cel in the treatment of people with SCD and assigned a Prescription Drug User Fee Act (PDUFA) action date of December 8, 2023. Exa-cel’s Biologics License Application (BLA) for transfusion-dependent beta-thalassemia (TDT) was assigned a PDUFA date of March 30, 2024.
Yes, TCON looks promising!
Yes, it looks promising!
Nice, Dad! I think it has some good upside potential
Yes, TCON looking good!
Yes, I agree. Holding PROK into next week.
PROK looks good. Bought it at $2.13. Clear skies ahead, LOL.
I agree
Thanks. TCON looks good, so I bought a little at $0.195.
I was lucky enough to buy CDIO at $1.66 today. Tomorrow should be interesting
Nice, yeah wish I had sold over 70 cents, but sold all of my shares from back then between 60 cents and around 35 cents. Then bought back last year
It was never over $1 a share. I am pretty sure the pre-split high was 90 cents. I started selling around 60 cents.
Thanks for the info!!
Thanks! It's definitely intriguing! Only time will tell
It may be nothing, but we don't know since it wasn't disclosed who the contract was for.
Valaris Bags Contract for 12 Wells Offshore West Africa
by Rocky Teodoro| Rigzone Staff| Thursday, August 03, 2023
Offshore drilling services provider Valaris Limited has won a 12-well contract offshore West Africa for the drillship VALARIS DS-7, which will be reactivated for this contract, the company said.
The $364 million contract is expected to begin in the second quarter of 2024 and has an estimated duration of 850 days, Valaris said in a recent news release.
Valaris said the contract “requires minimal customer-specific upgrades to the rig” and does not include the provision of any additional services. The provider of the contract was not disclosed.
https://www.rigzone.com/news/valaris_bags_contract_for_12_wells_offshore_west_africa-03-aug-2023-173541-article/
You're wrong nwtf. The WSJ will not list a share price to more than 4 decimal places. You have a few shares, you should have seen the price in your account, but I guess you didn't check the share price that day.
LOL, sorry buddy
No, you are wrong. I know what the fucking price was, so don't fucking tell me no.
No sir. I know what I saw, and I wasn't the only one who saw it. That's why we posted about it when it happened. Maybe what you are looking up shows 0.0001 as the default lowest their system can show.
It was actually 5 zeros:
Auman
Re: None
Tuesday, September 21, 2021 1:13:58 PM
Post#
347918
of 357453
So if my math is correct, ERHE went from .000001 to .0015, a 150,000% increase in a week?
Thanks for the info!
Wow, share price up 400% to 0.0020 today. Low volume, but still interesting.